Key Points
- Xeris Biopharma insider Kevin McCulloch sold 25,000 shares for $250,000 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 1.53% to 1.61 million shares.
- Xeris shares opened at $9.98, up 1.5%, and have risen above their 50-day and 200-day moving averages. The company recently reported a quarterly EPS loss of $0.18, missing estimates, despite revenue of $92.1 million that exceeded expectations.
- Analyst sentiment is mixed but leans positive, with a consensus “Hold” rating and a $12.80 price target; institutional investors own 42.75% of the stock after several major funds established or expanded positions.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin McCulloch sold 25,000 shares of the firm's stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider owned 1,614,208 shares in the company, valued at approximately $16,142,080. This trade represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kevin Mcculloch also recently made the following trade(s):
- On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total value of $127,350.00.
- On Monday, August 3rd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.02, for a total value of $120,300.00.
- On Wednesday, July 1st, Kevin McCulloch sold 90,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total transaction of $722,700.00.
Xeris Biopharma Stock Up 1.5%
Xeris Biopharma stock opened at $9.98 on Wednesday. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -90.73 and a beta of 0.70. The company's 50 day simple moving average is $8.41 and its 200 day simple moving average is $7.23. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $11.33.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research firms recently commented on XERS. Leerink Partners upped their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an "outperform" rating in a research report on Thursday, September 10th. Weiss Ratings lowered Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Barclays boosted their target price on Xeris Biopharma from $9.00 to $12.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Finally, Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "buy" rating in a report on Saturday, September 19th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Xeris Biopharma has a consensus rating of "Hold" and a consensus price target of $12.80.
Get Our Latest Stock Report on Xeris Biopharma
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Xeris Biopharma during the second quarter worth $115,042,000. Legal & General Group Plc acquired a new stake in shares of Xeris Biopharma during the second quarter worth $15,941,000. Parkman Healthcare Partners LLC bought a new stake in Xeris Biopharma in the 2nd quarter valued at $14,316,000. Bank of America Corp DE bought a new stake in Xeris Biopharma in the 2nd quarter valued at $11,065,000. Finally, Granahan Investment Management LLC lifted its position in Xeris Biopharma by 249.4% in the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company's stock valued at $9,604,000 after acquiring an additional 873,236 shares in the last quarter. Institutional investors own 42.75% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc (NASDAQ:XERS) is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.
The company's commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing's syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
